We previously reported that brain-derived neurotrophic factor (BDNF) regulates both food intake and blood glucose metabolism in rodent obese diabetic models such as C57BL/KsJ-lepr N eurotrophins are important regulators in the embryogenesis, development, and functioning of nervous systems (1,2). At present, four neurotrophins are known: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-3, and NT-4 / N T-5 (3-6) in mammals. BDNF, discovered long after NGF, enhances the survival and differentiation of several classes of neurons in the central and peripheral nervous systems, including motoneurons and sensory neurons. BDNF and its receptor, TrkB, are widely expressed in a variety of neurons through the embryonic, postnatal, and adult stages (7-10). These results and the many activities of BDNF described in in vitro cell cultures and lesioned animal studies (11,12) indicate that BDNF is likely to have multiple functions.
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We previously reported that brain-derived neurotrophic factor (BDNF) regulates both food intake and blood glucose metabolism in rodent obese diabetic models such as C57BL/KsJ-lepr N eurotrophins are important regulators in the embryogenesis, development, and functioning of nervous systems (1, 2) . At present, four neurotrophins are known: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-3, and NT-4 / N T-5 (3-6) in mammals. BDNF, discovered long after NGF, enhances the survival and differentiation of several classes of neurons in the central and peripheral nervous systems, including motoneurons and sensory neurons. BDNF and its receptor, TrkB, are widely expressed in a variety of neurons through the embryonic, postnatal, and adult stages (7) (8) (9) (10) . These results and the many activities of BDNF described in in vitro cell cultures and lesioned animal studies (11, 12) indicate that BDNF is likely to have multiple functions.
In addition to the efficacy of BDNF in neurological disorders, we previously found that BDNF reduces food intake and blood glucose concentration in rodent obese diabetic models, such as C57BL/KsJ-d b/d b mice (13, 14) . To eliminate the effect of reduced food intake on the regulation of glucose metabolism, we evaluated the hypoglycemic effect of BDNF in d b/d b mice using the conventional pair-feeding protocol in which the amount of food provided to each pair-fed mouse was the same as the average amount of food eaten by the BDNF-treated mice during the preceding 24-h period (13, 14) . H o w e v e r, because such hyperphagic diabetic mice given a vehicle ate all of the food over a period of several hours, leaving them in a fasting condition until the next feeding, this protocol was inappropriate to study the effect of antidiabetic agents on glucose metabolism by mechanisms other than appetite alteration.
In this study, to overcome these drawbacks, we designed a novel pellet pair-feeding apparatus and evaluated the effect of BDNF on glucose metabolism by precisely synchronizing food intake between BDNF- 
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uate this expected effect of BDNF on insulin action, we conducted a detailed investigation of the relationship between BDNF and insulin using streptozotocin-induced type 1 diabetic mice. In addition, we studied the insulin content and histochemical changes in the pancreas from BDNF-treated d b/d b mice. To evaluate the antidiabetic effect of BDNF on another animal model, we demonstrated the efficacy of BDNF on impaired glucose tolerance of KK mice, normoglycemic obese animals (20). We then tried to ascertain how blood glucose is metabolized in BDNF-treated animals. Because BDNF increased neither body weight nor fat weight in d b/d b mice, it seemed likely that BDNF enhanced the energy expenditure in these animals. To test this hypothesis, we measured body temperature and oxygen consumption of d b/d b mice to determine the role of BDNF in the regulation of energy metabolism.
L a s t l y, to clarify the action mechanism of BDNF, we evaluated the effect of intracerebroventricular administration of BDNF on d b/d b mice. Below, we discuss the antidiabetic effects of BDNF in diabetic models.
RESEARCH DESIGN AND METHODS
A n i m a l s . Male C57BL/KsJ-d b/db mice were obtained from Clea Japan (To k y o ) . Mice were singly housed and were used for the experiment at 11-12 weeks of age. Age-matched male heterozygous C57BL/KsJ-d b/m mice were used as a nondiabetic control. Male C57BL/6Ncrj mice were obtained from Charles River Japan (Yo k ohama, Japan) and were treated with streptozotocin (STZ) at 8 weeks of age. Male KK mice were obtained from Clea and used for the experiment at 12 weeks of age. Animals were given food and water ad libitum, except during the pair-f e e ding experiment. All animal experiments were conducted according to the guidelines of the Sumitomo Pharmaceuticals Committee on Animal Research. Synchronized pair-feeding apparatus. A synchronized pellet pair-f e e d i n g apparatus was newly developed (Sumitomo Pharmaceuticals, Osaka, Japan, and Osaka Micro Systems, Settsu, Japan) to carry out experiments under precise p a i r-feeding conditions. The apparatus is composed of a controller, counter p r i n t e r, and eight pairs (master and slave) of cage units (Fig. 1A ). There are a pellet feeder and pellet detector in each cage unit; each of the eight cage unit pairs is independently controlled. The supply of pellets to the master cage is not limited, but the supply of pellets to the slave cage is limited to the number of pellets consumed by the mouse in the master cage. The number of pellets consumed in each cage unit is recorded per unit time. Administration of BDNF. Human recombinant BDNF (NH 2 -terminal methioninefree; Regeneron Pharmaceuticals, Tarrytown, NY) was administered subcutan e o u s l y. Phosphate-buffered saline (PBS) or 0.01% Tween 80 and 1% Mannitol in PBS was used as a vehicle. For intracerebroventricular administration, d b/d b mice were anesthetized with diethyl ether, the bregma was identified through the skin, and 15 µg/mouse of BDNF (~3 µl/shot) was injected into the third cerebral ventricle every other day (total five times). Induction of diabetes by STZ and experimental protocols. Diabetes was induced in C57BL/6Ncrj mice by two consecutive daily intraperitoneal injections of STZ (200 mg/kg) (Sigma, St. Louis, MO) dissolved in citrate buffer (pH 5.5). On the third day after the last STZ injection, the diabetic mice were divided into four groups. Treatment for each group was as follows: group 1, PBS and saline; g r o u p 2, BDNF and saline; group 3, PBS and insulin (0.5 U/kg) (Novo Nordisk, Copenhagen); and group 4, BDNF and insulin. BDNF or PBS was administered 1 h before insulin or saline administration (subcutaneously). It was necessary to maintain fasting in all groups after BDNF or PBS administration, since BDNF treatment reduced food intake in STZ-induced diabetic animals (data not shown). Oral glucose tolerance test. After a period of overnight fasting, 3g/kg D-g l u c o s e was administered orally to KK mice. Blood glucose concentrations were measured at 0 min (before) and 15, 45, 95, and 135 min after glucose administration. Plasma insulin concentrations were also measured at 0 min (before) and 15, 45, and 135 min after glucose administration. Measurement of blood glucose and percent HbA 1 c . Blood samples were collected from the tail vein, and blood glucose was measured by the Glucose C-Te s t Wako (Mutarotase-glucose oxidase method; Wako Chemical, Osaka, Japan) or with a blood glucose analyzer (Antsense II; Daikin, Osaka, Japan). Percent HbA 1 c w a s measured by DCA2000 (Bayer-Sankyo, Tokyo) according to the manufacturer's protocol (21). Histological analysis and measurement of insulin and glucagon. Blood samples were collected from tail vein, and plasma insulin concentrations were measured by enzyme-linked immunosorbent assay (ELISA) (Levis-insulin-mouse; Shibayagi, Gunma, Japan). At the end of the treatment, the whole pancreas was resected from each mouse and divided into splenic and duodenal regions. Splenic regions were weighed, minced, and homogenized in acid-ethanol solution (75% ethanol, 23.5% distilled water, 1.5% concentrated HCl). After overnight incubation at 4°C, the suspensions were centrifuged, and the supernatants were collected and assayed for insulin content (see above). Pancreatic glucagon content was measured by radioimmunoassay (Linco Research, St. Louis, MO). Duodenal regions were fixed in Bouin's solution, embedded in paraffin, sectioned (3 µm), and stained using Gomori's aldehyde-fuchsin technique (22) or the immunohistochemical method (anti-insulin, anti-glucagon, or anti-somatostatin). Body temperature and themographic imaging analysis. Body temperature was measured using an electron thermistor (Model BAT-12; Physitemp, Clifton, NJ), equipped with rectal probe (RET-3; Physitemp). Skin temperature was imaged by thermography (TVS-8000MkII; Abionics, To k y o ) . Oxygen consumption. Oxygen consumption was measured with an O 2 / C O 2 metabolism measuring system (Model MK-5000; Muromachikikai, Tokyo). Each mouse was placed in a sealed chamber (560 ml volume) with an air flow of 0.18 l/min for ~3 h at 25°C. Air was taken every 3 min, and the consumed oxygen concentration was converted to milliliters per minute by multiplying it by the flow rate. Statistical analysis. All data were presented as means ± SD. Differences between individual groups were analyzed by the Student's t test, Tukey-Kramer test, Wi l l i a m 's test, or Dunnett's test. The statistical calculations were performed using SAS software (SAS Institute, Cary, NC). P < 0.05 was considered statistically signific a n t .
R E S U LT S
Control of food intake with a synchronized pellet pairfeeding apparatus. We have previously shown that BDNF reduces both blood glucose concentration and food intake in d b/d b diabetic mice (13, 14) . To elucidate the actual role of BDNF on glucose metabolism, it is very important to know whether or not the hypoglycemic effect of BDNF is due solely to appetite reduction. Therefore, in this study, we have developed a new synchronized pellet pair-feeding apparatus to control food intake precisely between BDNF- Even under these precise pellet pair-feeding conditions, the blood glucose concentration of the BDNF-treated mice was reduced gradually and was found to be significantly lower than the pair-fed control mice after 8 days of BDNF administration (Fig. 2B) . Furthermore, repetitive administration of BDNF did not induce hypoglycemia. Body weights decreased almost identically in both the BDNF-treated and pair-fed vehicle-treated groups (Fig. 2C ) . E ffect of BDNF on glycemic control of STZ-induced t y p e 1 diabetic mice. We have previously reported that the efficacy of BDNF in lowering blood glucose concentration was stronger in younger more hyperinsulinemic d b/d b m i c e than in older less hyperinsulinemic mice (13) . In our previous s t u d y, we showed that BDNF had no effect on blood glucose HYPOGLYCEMIC ACTION OF BDNF in the STZ-induced model (13) . To confirm the effect of BDNF on insulin action, we evaluated the efficacy of BDNF in STZ mice with and without insulin co-administration. As shown in Fig. 3 , monotherapy with BDNF did not reduce blood glucose concentration in the experiment. However, when administered concomitantly with insulin, BDNF showed a significant hypoglycemic effect compared with vehicle-treated STZ mice. Moreover, the blood glucose concentration of the STZ mice that received a combination of BDNF and insulin was significantly lower than insulintreated mice at 1 and 2 h after insulin administration. Blood glucose concentrations of insulin-treated mice, irrespective of BDNF treatment, returned to pretreatment levels within 3 h after insulin treatment. These data indicate that BDNF enhances the hypoglycemic action of insulin.
Antidiabetic effect of BDNF on KK mice. Our findings in this study showed that BDNF is effective on obese hyperglycemic diabetic d b/d b mice and that combination therapy with insulin is effective on lean STZ-induced mice. We then decided to study the effect of BDNF on KK mice, normoglycemic animals with impaired glucose tolerance. After daily subcutaneous administration of 5 or 20 mg/kg BDNF for 3 weeks, blood glucose concentrations of KK mice given BDNF were significantly lowered during the oral glucose tolerance test compared with KK mice given vehicle (Fig. 4A ) . This decrease, taken together with the lower plasma insulin concentrations in BDNF-treated KK mice (Fig. 4B) , indicates that BDNF improves impaired glucose tolerance in KK mice. Although blood glucose concentrations of KK mice given BDNF were lowered to some extent by the reduced food intake, glucose concentrations and HbA 1 c levels were within normal levels (Ta b l e1 ) . (Fig. 5B) . These data correlated well with the pancreatic insulin content obtained by ELISA (Ta b l e 2 ) .
Immunohistochemical staining with anti-glucagon antibody was also used to identify pancreatic -cells in the d b/d b mice (Fig. 5C) . Staining with anti-glucagon antibody was obscure in most, if not all, of the islets from mice given vehicle with only a very few glucagon-positive cells found in the islets. In contrast, glucagon-positive cells were located peripherally in the islets from BDNF-treated mice, indicating a normalized cell distribution. Similar results were obtained with immunostaining for somatostatin (Fig. 5D) . BDNF prevented the reduction of body temperature in the food-restricted d b/d b mice. Our results showed that under precise pellet pair-feeding conditions, the blood glucose concentration of BDNF-treated mice was significantly lower than the vehicle-treated mice (Fig. 2B) . There was no significant difference between fat weights (subcutaneous and intraperitoneal) of d b/d b mice given BDNF and pellet pair-f e d d b/d b mice given vehicle (data not shown), nor was there any s i g n i ficant difference in body weights (Fig. 2C) . To elucidate how blood glucose was metabolized, body temperature was measured as one of the indices of energy expenditure. Leptin-resistant d b/db mice show a reduced energy metabolism and lower body temperature, similarly to leptin-defic i e n t o b/o b mice (23-26). Furthermore, they are thought to be unable to activate thermogenesis and maintain body temperature when their food intake is restricted. In the control (Fig. 7A ). Under such strict pellet pair-f e e ding conditions, intracerebroventricular administration of 1 5 µg/mouse BDNF (five times every other day) signific a n t l y lowered blood glucose concentrations in d b/d b m i c e ( F i g . 7B). As shown in Fig. 7B , blood glucose concentrations in the BDNF-treated mice remained significantly lower than those in the vehicle-treated mice for an additional 25 days after completion of treatment. This result indicates that intracerebroventricular administration of BDNF shares the same anorectic and hypoglycemic actions seen in peripheral a d m i n i s t r a t i o n .
D I S C U S S I O N
We have previously shown that BDNF reduces food intake together with blood glucose in obese diabetic d b/d b m i c e (13, 14) . Our interest was then focused on determining whether BDNF actually regulates glucose metabolism by a mechanism other than appetite alteration. In our initial attempt, we used a conventional pair-feeding protocol and demonstrated the hypoglycemic effect of BDNF on d b/d b mice. However, because these diabetic mice are very hyperphagic, pair-fed control d b/d b mice under such a protocol usually eat all of the food within several hours, leaving them in a fasting condition for almost half a day. Accordingly, patterns of food intake during the day are quite different between BDNF-treated and pair-fed vehicle-treated mice. Worse yet, blood glucose concentrations in the pair-fed mice, if measured before the next feeding, must be reduced because of the long fasting period. Thus, this is an inappropriate control group to study the effects of antidiabetic agents on glucose metabolism by mechanisms other than appetite regulation.
In this study, we designed a novel pellet pair-feeding apparatus and succeeded in precisely synchronizing food intake between BDNF-treated d b/d b mice and vehicle-treated control mice. We then clearly demonstrated that BDNF given to d b/d b mice brings on a significant hypoglycemic effect compared with pellet pair-fed mice. This finding demonstrates that BDNF plays a regulatory role in glucose metabolism independently of appetite alteration in obese diabetic mice. In these experiments, where both the amount of food and the feeding pattern were precisely matched using our apparatus, reductions in body weights and fat weights of both the BDNF-treated mice and pellet pair-fed mice were found to be nearly the same. BDNF neither made these mice too thin nor aggravated their obesity. In this study, the pellet pair-f e d This action of BDNF may share some features with the anorectic protein leptin, which has been reported to regulate appetite and energy expenditure. It has been suggested that leptin administered by the peripheral route produces these effects through its action on the hypothalamus (27) (28) (29) , the regulatory center of the autonomic nervous system controlling both food intake and energy expenditure (30) . The present results with intracerebroventricular administration indicate that BDNF acts on the brain and produces its hypoglycemic and anorectic effects via the central nervous system. Intracerebroventricular administration of BDNF in doses as small as 15 µg/mouse (~300 µg/kg) proved to be effective in lowering blood glucose concentrations. Furthermore, intracerebroventricular administration of only 1.5 µg/mouse (~30 µg/kg) BDNF was also found effective (data not shown). Such doses are roughly 1/100 and 1/1,000 of those used in subcutaneous administration. In addition, these doses of BDNF were not effective when delivered peripherally (M.O., Y. I . , T.No., T.Na., C.N., M.T., H.N., unpublished observations). Therefore, it is reasonable to assume that when BDNF is administered subcutaneously, a small portion of the dose enters the brain and is directly responsible for lowering blood glucose concentrations. Because the BDNF receptor, TrkB, is expressed also in the hypothalamus (10), BDNF may regulate glucose metabolism by modulating the autonomic function in this region.
We have previously reported that the hypoglycemic action of BDNF was stronger in younger more hyperinsulinemic d b/db mice than older less hyperinsulinemic mice (13) . BDNF was thus seen to exert its hypoglycemic action most efficiently in d b/d b mice with sufficient plasma insulin levels. These data indicate that BDNF facilitates insulin action and lowers blood glucose concentrations in obese diabetic mice. In the current study of the effect of BDNF on insulin action, we found that BDNF itself does not lower the blood glucose concentration but enhances insulin action in STZ mice. M o r e o v e r, only a single administration of BDNF was effective in enhancing insulin action in STZ mice. This is the first evidence to show that BDNF acts quickly to enhance insulin action. In recent years, it has been reported that thiazolidinediones, newly discovered antidiabetic agents, increase insulin sensitivity in insulin-dependent glucose-utilizing tissues (31, 32) and, with repetitive administration, improve insulin resistance in obese diabetic animals and humans (33, 34) . It has also been reported that thiazolidinediones themselves have no effect on blood glucose concentration in the STZinduced diabetic model (35) but when administrated with a minimal dosage of insulin, improve insulin resistance (36) .
In addition to d b/d b mice, we have found that BDNF exhibits its hypoglycemic action in other obese diabetic animals, such as o b/o b mice, KKAy mice, and Zucker diabetic fatty rats (data not shown). Therefore, BDNF is effective in several obese hyperglycemic models, irrespective of genetic mutation sites, mutation types, or functional deficiencies. In combination therapy with insulin, BDNF is even effective on genetically normal but chemically induced hyperglycemic diabetic STZ-induced mice. These observations indicate that BDNF regulates glucose metabolism in a variety of hyperglycemic diabetic animals. Furthermore, in this study, we demonstrated that BDNF ameliorates impaired glucose tolerance of a normoglycemic obese animal-the KK mouse. This means that BDNF improves insulin resistance in these animals without severe glucose toxicity.
Thiazolidinediones are thought to enhance the insulin sensitivity in the peripheral tissues by activating peroxisome prol i f e r a t o r-activated receptor-( P PA R -), a subtype of the nuclear receptor superfamily expressed in adipose tissue (37) . On the other hand, BDNF neither activates PPA R--dependent transcription nor enhances 2-deoxyglucose transport in cultured adipocytes and muscle cells (A.T., T.Na., Y. I . , J. Ichihara, M.T., H.N., unpublished observations). Thus, it is not likely that BDNF acts directly on peripheral tissues to enhance insulin action. Because BDNF is a neurotrophic factor that acts on both the central and peripheral nervous systems, it is natural to speculate that BDNF enhances insulin action indirectly via regulation of such neural pathways. Our results showed that intracerebroventricular administration of BDNF has the same hypoglycemic action as peripheral administration. These data apparently reinforce the action mechanism by which BDNF acts directly on the brain to regulate glucose metabolism, resulting in enhancement of insulin action in peripheral tissues.
We have also demonstrated that BDNF increases insulin content compared with pretreatment levels and restores granulated -cells in d b/d b mice pancreatic islets. This demonstration supports our previous results that BDNF lowers blood glucose levels of d b/d b mice, as determined by an oral glucose tolerance test (13, 14) . It is not likely that the effect of BDNF on the pancreas is due to lowered food intake, since there was no difference in pancreatic insulin content between the pellet pair-fed and ad libitum-fed controls. Because BDNF enhances insulin sensitivity and ameliorates insulin resistance, d b/db mice given BDNF require less insulin secretion from -cells to achieve prolonged near-n o rmoglycemia and increase both pancreatic insulin content and granulation of -cells. However, another possibility that cannot be excluded is that BDNF directly affects the pancreas and normalizes the function of islets. This view is supported by a report that pancreatic -cells express the BDNF recept o r, TrkB (38) , which in turn suggests a potential paracrine interaction between -and -cells in the islets. Intensive insulin therapy that manages blood glucose well and prevents progressive onsets of diabetic complications is expected to ameliorate pancreatic function in type 2 diabetic patients (39, 40) . Therefore, it should be emphasized that B D N F, in place of insulin, could be especially useful in restoring the pancreatic function of type 2 diabetic patients.
In summary, we report here that BDNF normalizes glucose metabolism and energy balance in type 2 diabetic mice and enhances the hypoglycemic effect of insulin in type 1 diabetic mice. Our findings confirm that this antidiabetic effect was not due to appetite alteration. Furthermore, it appears that BDNF ameliorates pancreatic dysfunction as well as insulin resistance. These antidiabetic effects are also observed in the intracerebroventricular administration of B D N F. Our results thus indicate that BDNF possesses a potentially useful profile as an antidiabetic agent.
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